Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Allogeneic transplantation in malignant lymphoma].
Stötzer OJ, Schleuning M, Ledderose G, Hiddemann W, Kolb HJ. Stötzer OJ, et al. Among authors: ledderose g. Dtsch Med Wochenschr. 2001 Sep 28;126(39):1062-9. doi: 10.1055/s-2001-17492. Dtsch Med Wochenschr. 2001. PMID: 11602913 German.
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ. Schmid C, et al. Among authors: ledderose g. Blood. 2006 Aug 1;108(3):1092-9. doi: 10.1182/blood-2005-10-4165. Epub 2006 Mar 21. Blood. 2006. PMID: 16551971 Free article. Clinical Trial.
Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F).
Holler E, Kolb HJ, Mittermüller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, et al. Holler E, et al. Among authors: ledderose g. Blood. 1995 Aug 1;86(3):890-9. Blood. 1995. PMID: 7620183 Free article. Clinical Trial.
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb HJ. Schmid C, et al. Among authors: ledderose g. Bone Marrow Transplant. 2008 Apr;41(8):721-7. doi: 10.1038/sj.bmt.1705965. Epub 2008 Jan 7. Bone Marrow Transplant. 2008. PMID: 18176613
Tolerance and chimerism.
Kolb HJ, Guenther W, Gyurkocza B, Hoetzl F, Simoes B, Falk C, Schleuning M, Ledderose G. Kolb HJ, et al. Among authors: ledderose g. Transplantation. 2003 May 15;75(9 Suppl):26S-31S. doi: 10.1097/01.TP.0000067948.90241.82. Transplantation. 2003. PMID: 12819487 Review.
Adoptive immunotherapy in chimeras with donor lymphocytes.
Kolb HJ, Schmid C, Chen X, Woiciechowski A, Roskrow M, Weber M, Guenther W, Ledderose G, Schleuning M. Kolb HJ, et al. Among authors: ledderose g. Acta Haematol. 2003;110(2-3):110-20. doi: 10.1159/000072460. Acta Haematol. 2003. PMID: 14583671 Free article. Review.
90 results